

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564

| | |
|------------|------------------|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 30 participants |

Key Eligibility Criteria

Inclusion (4)

- Male
- Age 18-64 years (both inclusive) at the time of signing the informed consent.
- Body weight greater than or equal to (e) 45 kilograms (kgs).
- Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than or equal to (d) 15 percentage (%) with or without FVIII inhibitors, based on medical records.

Exclusion (7)

- Current or prior exposure to any prophylactic treatment for haemophilia A within 5 half-lives of the medicinal product by the time of screening.
 - Body mass index ≥ 30.0 kilogram per square meter (kg/m^2).
 - Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.
 - Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
 - Any known coagulation disorders other than haemophilia A.
- ... and 2 more (see full listing online)

Locations (22 total)

UC Denver Hemoph & Thrombo Ctr, Aurora, Colorado, United States
Indiana Hemophilia-Thromb Ctr, Indianapolis, Indiana, United States
University of Iowa_Iowa City, Iowa City, Iowa, United States
... and 19 more locations